UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating

Published on 05/07/2025 at 09:47

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Myriad Genetics, Inc.

Myriad Genetics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02:00 PM	Jun. 11
Myriad Genetics, Inc. Announces Early Access to the FirstGene Multiple Prenatal Screen	Jun. 03	CI
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise Mrd Across Multiple Cancer Types	Jun. 02	CI
Sector Update: Health Care Stocks Fall Late Afternoon	May. 21	MT
Myriad Genetics Shares Fall After Downgrade From Scotiabank	May. 21	MT
Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	May. 21	MT
Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating	May. 19	MT
Myriad Genetics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03:00 PM	May. 15
Myriad Genetics Shares Drop After Downgrade From Wolfe Research	May. 08	MT
Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform	May. 08	MT
Myriad Genetics, Inc. Announces Riskscore Study Published in JCO Precision Oncology	May. 07	CI
UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating	May. 07	MT
Traders Weigh Tariff News Ahead of Fed Decision, Lifting US Equity Futures Pre-Bell	May. 07	MT
Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22	May. 07	MT
Myriad Genetics, Inc., Q1 2025 Earnings Call, May 06, 2025	May. 06
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Earnings Flash (MYGN) Myriad Genetics Posts Q1 Adjusted EPS $-0.03, vs. FactSet Est of $-0.05	May. 06	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Adjusted EPS Range $-0.02 - $0.02	May. 06	MT
Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025	May. 06	CI
Myriad Genetics Highlights MRD Clinical Validity Data At American Association for Cancer Research Annual Meeting	Apr. 25	CI
Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing	Apr. 21	CI
Guggenheim Downgrades Myriad Genetics to Neutral From Buy	Apr. 09	MT
Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer	Apr. 07	RE
Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025	Apr. 07	CI
Sector Update: Health Care Stocks Lower Late Afternoon	Mar. 12	MT